Literature DB >> 1981143

The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3.

O Alper1, K Yamaguchi, J Hitomi, S Honda, T Matsushima, K Abe.   

Abstract

The Mr 185,000 glycoprotein encoded by human c-erbB-2/neu/HER2 gene, termed c-erbB-2 gene product, shows a close structural similarity with epidermal growth factor receptor and is now regarded to be a growth factor receptor for an as yet unidentified ligand. Abundant c-erbB-2 mRNA was demonstrated by Northern blot studies in the human breast cancer cell line SK-BR-3. Cellular radiolabeling experiments followed by immunoprecipitation with three different anti-c-erbB-2 gene product antibodies, recognizing extracellular domain, kinase domain, and carboxyl-terminal portion, respectively, demonstrated the production of a large amount of c-erbB-2 gene product which had the capacity to be phosphorylated. Immunization of mice with concentrated culture medium conditioned by SK-BR-3 cells always generated antibodies against c-erbB-2 gene product, demonstrating that this culture medium contained substance(s) immunologically indistinguishable from c-erbB-2 gene product. This observation was supported by the successful development of a monoclonal antibody against c-erbB-2 gene product, GFD-OA-p185-1, by immunizing mice with this culture medium. The biochemical nature of the substance(s) present in the culture medium was further characterized. When the culture medium conditioned by [35S]cysteine-labeled SK-BR-3 cells was immunoprecipitated by three different anti-c-erbB-2 gene product antibodies, only the antibody recognizing extracellular domain precipitated the [35S]-labeled protein with a molecular weight of 110,000, namely p110. The newly developed monoclonal antibody also immunoprecipitated this protein.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981143

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  11 in total

1.  Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.

Authors:  A Esparís-Ogando; E Díaz-Rodríguez; A Pandiella
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  Avian reticuloendotheliosis virus strain A and spleen necrosis virus do not infect human cells.

Authors:  R Gautier; A Jiang; V Rousseau; R Dornburg; T Jaffredo
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.

Authors:  Ozge Alper; William G Stetler-Stevenson; Lyndsay N Harris; Wolfgang W Leitner; Metin Ozdemirli; Dan Hartmann; Mark Raffeld; Mones Abu-Asab; Stephen Byers; Zhengping Zhuang; Edward H Oldfield; Yanhe Tong; Elke Bergmann-Leitner; Wayne E Criss; Koichi Nagasaki; Samuel C Mok; Daniel W Cramer; F Seyda Karaveli; Raphaela Goldbach-Mansky; Paul Leo; Kurt Stromberg; Robert J Weil
Journal:  Cancer Sci       Date:  2009-06-17       Impact factor: 6.716

4.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

5.  Analysis of c-erbB2 protein content of human glioma cells and tumor tissue.

Authors:  H H Engelhard; M Wolters; P S Criswell
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

6.  A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.

Authors:  G K Scott; R Robles; J W Park; P A Montgomery; J Daniel; W E Holmes; J Lee; G A Keller; W L Li; B M Fendly
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

7.  Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients.

Authors:  B Kynast; L Binder; D Marx; B Zoll; H J Schmoll; M Oellerich; A Schauer
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  Isolation of the intact molecule and ectodomain of C-erbB-2 oncoprotein from SK-BR-3 cells and development of immunoassays on microplate.

Authors:  J T Wu; P Zhang; B W Lyons; L H Wu
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

9.  Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies.

Authors:  A Jiang; T H Chu; F Nocken; K Cichutek; R Dornburg
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.

Authors:  P Todeschini; E Cocco; S Bellone; J Varughese; K Lin; L Carrara; F Guzzo; N Buza; P Hui; D-A Silasi; E Ratner; M Azodi; P E Schwartz; T J Rutherford; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2011-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.